A study conducted by Qin et al. [143] identified a high pre-treatment serum ALB–BIL grade combined with pre-treatment clinically significant portal hypertension (CSPH) as an independent predictor for worse OS and RFS in HCC patients undergoing curative surgical resection. The gene discussed is ALB; the disease is hepatocellular carcinoma.